Incident users of tyrosine kinase inhibitors in patients with chronic myeloid leukemia: Analysis of anticancer treatment trajectories—A French population‐based study using the French national health data system
- 7 June 2022
- journal article
- letter
- Published by Wiley in American Journal of Hematology
- Vol. 97 (8) , E307-E309
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Patterns of Tyrosine Kinase Inhibitor Utilization in Newly Treated Patients With Chronic Myeloid Leukemia: An Exhaustive Population-Based Study in FranceFrontiers in Oncology, 2021
- Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML studyBritish Journal of Haematology, 2020
- Using healthcare claims data to analyze the prevalence of BCR‐ABL‐positive chronic myeloid leukemia in France: A nationwide population‐based studyCancer Medicine, 2019
- Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic‐phase chronic myeloid leukemia in routine clinical practice: SIMPLICITYAmerican Journal of Hematology, 2018
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Blood, 2013